Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 29, 2012

Schizophrenia Drug Fails in Phase III

  • Lilly is pulling the plug on Phase III development of its schizophrenia candidate pomaglumetad methionil (mGlu2/3) because an independent analysis of data from a second Phase III study (designated HBBN) concluded that the drug simply doesn’t seem to work. A recently completed Phase II trial (HBCO) that evaluated pomaglumetad methionil as an adjunctive treatment to atypical antipsychotics also failed to meet its primary endpoint.

    Lilly says discontinuing Phase III development of the drug will result in an expected third-quarter charge related to R&D expense of some $25–$30 million, pre tax. While the firm admits it’s disappointed with the failure of pomaglumetad methionil, it says it still has about a dozen neuroscience candidates in its clinical pipeline, targeting diseases including depression, bipolar disorder, and cognitive impairment associated with schizophrenia.

Related content


GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

What Does Brexit Mean for Biotech?

Do you agree with the contention that Brexit will NOT have a long-term negative impact on the British biotech industry?

More »